Sponsor content
212 result(s) found, displaying 51 to 60
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ICLUSIG ponatinib (as hydrochloride) 30 mg film-coated tablet bottle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ICLUSIG ponatinib (as hydrochloride) 10 mg film-coated tablet bottle.
-
Australian public assessment report (AusPar)AusPAR for Livtencity (maribavir) for the treatment of adults with post-transplant cytomegalovirus (CMV) infection and disease resistant, refractory or intolerant to one or more prior therapies
-
Prescription medicine registrationActive ingredients: vedolizumab.
-
Australian public assessment report (AusPar)AusPAR for Exkivity (Mobocertinib) for treatment of patients with locally advanced or metastatic non-small lung cancer.
-
Designation or determinationOrphan drug
-
Prescription medicine decision summaryLivtencity (maribavir) is approved to treat cytomegalovirus (CMV).
-
Prescription medicine registrationActive ingredients: maribavir.
-
Designation or determinationOrphan drug
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Mesalazine 1.2 TAKEDA (mesalazine) 1.2 g prolonged release tablet blister pack.